Tscan Therapeutics (TCRX): Director received 67K units

67K

Derivative units

Traded

May 20, 2026

Filed

May 22, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 31, 2026, Leiden Dworak notified TScan Therapeutics, Inc. (the “Company”) of his decision to resign as Vice President of Finance of the Company and principal accounting officer effective April 10, 2026.”
2. May 6, 2026Company filing · Form 8-K · ResultsReported its results
3. May 20, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote

What came next

1. Aug 12, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 12, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
3. Aug 27, 2026Company filing · Form 8-K · Restructuring, Listing noticeAnnounced job cuts, closures or a restructuring, and received a notice from its stock exchange (and 3 more items)“Departure of Certain Officers In connection with the Strategic Reorganization, effective as of September 2, 2026 (the “Effective Date”), the employment of Jason A. Amello, the Company’s Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company’s Chief Medical Officer, was terminated.”
4. Sep 8, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 8, 2026, the Compensation Committee of the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) approved a retention program designed to retain the employees required to support the Company, including a key employee retention program (the “Retention Program”) that provides for cash awards and the potential future grant of equity-based awards to certain key employees of the…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tscan Therapeutics

OQRO holds no insider, Congress, fund or contract record for Tscan Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TCRX page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Tscan Therapeutics

• SEC Form 4Dec 23, 2025
• SEC Form 4Dec 23, 2025
• SEC Form 4Dec 23, 2025
• SEC Form 4May 21, 2025
• SEC Form 4May 21, 2025
• SEC Form 4Dec 16, 2024

Everything OQRO holds on this company is on its TCRX page.